[Webinar] Immunodeficient Mouse Models for Cancer & Immunotherapy Research: NCG Mice (20220426 2nd)

Speakers:
Dr. Santi Suryani Chen, Associate Director of Immunology and Oncology
Dr. Zhiying Li, Directory of Life Science and Technology

The development of immunodeficient mouse models has advanced our understanding of how cancer progresses and has drastically improved oncology and immuno-oncology drug development research. GemPharmatech has carefully developed the NCG mouse strain, which lacks T, B, and NK cells, making it one of the most comprehensive immunodeficient mouse models available. Our NCG mice are powerful tools for modeling human diseases and are widely used for cancer immunotherapy research using cell derived xenografts (CDX) and patient derived xenografts (PDX). These mice are also ideal for immune system reconstitution using human peripheral blood mononuclear cells (PBMC) or human hematopoietic stem cells (HSC).

Topics for this webinar include:
An introduction to our NCG mice
Discussion about the advantages, benefits, and limitations of our NCG mouse models
Overview of our Next-Generation NCG strains and their role in oncology research
Applications for using humanized and immune reconstituted NCG mice for evaluation of oncology drug development


#Neurodegenerativedisease #Alzheimersdisease #animalmodels #drugdevelopment #translationalmedicine #KOAP #knockoutallproject #CrisprCas9 #genomeediting #knockout #conditionalknockout #mousemodel #metabolicdisease #autoimmunedisease #oncology #CART #CARNK #immunotherapy #immunodeficient